The Korea Times close
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Business
  • Tech
  • Bio
  • Companies
Finance
  • Companies
  • Economy
  • Markets
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
Entertainment
& Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
Sports
World
  • SCMP
  • Asia
Video
  • Culture
  • People
  • News
Photos
  • Photo News
  • Darkroom
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Sun, May 29, 2022 | 05:33
Business
Celltrion ships biosimilar medicine to US
Posted : 2016-08-19 19:07
Updated : 2016-08-19 19:56
Print Preview
Font Size Up
Font Size Down
By Kim Tae-gyu

Celltrion CEO Kim Hyoung-ki
Celltrion CEO Kim Hyoung-ki
Korean pharmaceutical firm Celltrion shipped the first batch of its biosimilar medicine Remsima to the U.S. Friday, a day after winning a U.S. lawsuit on sales of the autoimmune disorder drug.

Celltrion said that the move will accelerate the U.S. launch of Remsima, a biosimilar version of Janssen's Remicade. Remsima was put on sale in Europe in 2013.

Pfizer will take charge of sales of Remsima in the U.S., which will soon be available to U.S. patients suffering from rheumatoid arthritis and ulcerative colitis under the brand name of Inflectra in the world's largest pharmaceutical market.

"There remain more procedures before the biosimilar medicine actually hits the U.S. market. Pfizer will put forth efforts to deal with them although we will keep cooperating," a Celltrion official said.

"We believe that our victory in the patent suit cleared the biggest hurdle, which prompted us to start shipment."

Seeking a preliminary injunction to prevent Celltrion from selling Remsima, Janssen filed a complaint in June, two months after the drug received approval from the Federal Drug Administration (FDA).

But the district court ruled against Janssen this week and the firm plans to appeal the decision to an upper court. Yet, Celltrion said that the verdict would not be overturned.

"That's why we are starting to send our products to the U.S. We will put forth efforts to speed up all the necessary procedures," the official said.

Celltrion expects that the U.S. debut of Remsima will boost the company's bottom line as the U.S. autoimmune disease medicine market is estimated to be bigger than $17 billion a year.

Its original drug Remicade, which was developed by Janssen in 1998, had sales of $4.5 billion in the U.S. and $9.9 billion worldwide last year, making it one of the world's most profitable blockbuster medicines.

In a press conference this April, Celltrion CEO Kim Hyoung-ki projected that the company will earn more than $1.7 billion in the U.S. next year, assuming a double-digit market share.

The CEO said at the press conference that the biosimilar medicine will be on the shelf "in the fourth quarter of this year."

In Europe, the firm said that Remsima accounts for more than 30 percent of the market and the proportion would increase to somewhere between 40 percent and 50 percent.

"Based on the trust of European physicians and patients, we expect that penetration into the U.S. market will take place at a much faster pace," the company said in a statement.

Emailvoc200@koreatimes.co.kr Article ListMore articles by this reporter
 
  • Korean Mental Health: Stranger Things
  • Dutch Korean artist's project: The Mother Mountain Institute of Sara Sejin Chang
  • S. Korea's new COVID-19 cases below 20,000 for 3rd day as pandemic slows
  • Why Mario Outlet founder keeps buying houses of former presidents
  • KOICA launches interactive town in metaverse for overseas volunteer program
  • Union agress to resume late-night subway services in Seoul starting next month
  • 'Russia needs huge financial resources for military operations'
  • Uvalde school police chief faulted in shooting response
  • Former rhythmic gymnast Son Yeon-jae to wed in August
  • Koreans hit polls on last day of early voting for local elections
  • Korean films make splash at Cannes Film Festival Korean films make splash at Cannes Film Festival
  • From BTS to TWICE's Nayeon, K-pop hotshots prepare June releases From BTS to TWICE's Nayeon, K-pop hotshots prepare June releases
  • How did BTS become beacon of diversity and inclusion? How did BTS become beacon of diversity and inclusion?
  • K-pop band BTS and Biden to meet to discuss Asian inclusion, discrimination K-pop band BTS and Biden to meet to discuss Asian inclusion, discrimination
  • For new cultural policy for hallyu For new cultural policy for hallyu
DARKROOM
  • 75th Cannes Film Festival

    75th Cannes Film Festival

  • People in North Korea trapped in famine and pandemic

    People in North Korea trapped in famine and pandemic

  • 2022 Pulitzer Prize: Bearing witness to history

    2022 Pulitzer Prize: Bearing witness to history

  • Worsening drought puts millions at risk

    Worsening drought puts millions at risk

  • Our children deserve the best

    Our children deserve the best

The Korea Times
CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Location
  • Media Kit
  • Contact Us
  • Products & Service
  • Subscribe
  • E-paper
  • Mobile Service
  • RSS Service
  • Content Sales
  • Policy
  • Privacy Statement
  • Terms of Service
  • 고충처리인
  • Youth Protection Policy
  • Code of Ethics
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group